Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the underserved bipolar depression market will be attributable largely to an increase in diagnosis and drug-treatment rates during the next decade. Diagnosis rates will reach as high as 66% in the United States, and drug-treatment rates will climb as high as 80% in the United States, United Kingdom, France, Germany, Italy, Spain, and Japan.

According to the new Pharmacor report Bipolar Depression, growth in the market will also be driven by regulatory approval of drugs to treat bipolar depression, and the consequent increased recognition of treating the disorder's depressive symptoms. AstraZeneca's Seroquel (quetiapine), which is already used as an antipsychotic, will be the second drug, after Eli Lilly's Symbyax (olanzapine and fluoxetine capsules) to receive approval for treatment of bipolar depression.

"This line extension for Seroquel will create slight growth in sales attributable to bipolar disorder, but Seroquel's biggest competitor is itself, because many bipolar patients are already treated with the drug to manage manic or psychotic symptoms," said Kate Hohenberg, therapeutic area director at Decision Resources, Inc. "But the approval for treating depression is a logical line extension, and we expect that Seroquel's biggest drawback -- its tendency to cause sedation -- will actually serve it well if AstraZeneca promotes this side effect as an added benefit of depression therapy, especially in patients with comorbid insomnia."

About Bipolar Depression

Depression plays a prominent role in the profile of bipolar disorder because it is the most common symptom suffered by people with this disease. However, there are few effective treatments for the depressive symptoms of bipolar disorder and few novel agents will enter the market in the next decade.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Marketing Campaigns and Increasing Public Awareness Maintain Growth in the Minimally Invasive Surgery Spinal Fusion Market

View Now